Grifols, S.A. (GRFS)
NASDAQ: GRFS · Real-Time Price · USD
9.09
-0.01 (-0.11%)
At close: Nov 13, 2024, 4:00 PM
9.05
-0.04 (-0.44%)
After-hours: Nov 13, 2024, 4:23 PM EST
Grifols Revenue
Grifols had revenue of 1.79B EUR in the quarter ending September 30, 2024, with 12.24% growth. This brings the company's revenue in the last twelve months to 7.01B, up 7.21% year-over-year. In the year 2023, Grifols had annual revenue of 6.59B with 8.71% growth.
Revenue (ttm)
7.01B EUR
Revenue Growth
+7.21%
P/S Ratio
n/a
Revenue / Employee
295,156 EUR
Employees
23,737
Market Cap
7.26B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 6.59B | 528.01M | 8.71% |
| Dec 31, 2022 | 6.06B | 1.13B | 22.92% |
| Dec 31, 2021 | 4.93B | -406.92M | -7.62% |
| Dec 31, 2020 | 5.34B | 241.35M | 4.73% |
| Dec 31, 2019 | 5.10B | 611.97M | 13.64% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Walgreens Boots Alliance | 147.66B |
| Bausch + Lomb | 4.68B |
| Elanco Animal Health | 4.45B |
| Jazz Pharmaceuticals | 3.99B |
| Halozyme Therapeutics | 947.36M |
| Legend Biotech | 520.18M |
| Ascendis Pharma | 340.33M |
| Avidity Biosciences | 10.12M |
GRFS News
- 5 days ago - Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors - Business Wire
- 6 days ago - Grifols on track to meet 2024 targets despite third-quarter profit drop - Reuters
- 5 weeks ago - Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down - Seeking Alpha
- 6 weeks ago - Grifols plans to invest $402 million in new industrial centre, El Economista says - Reuters
- 7 weeks ago - Significant Shareholders Exercise Right to Grifols Board Seat - Business Wire
- 2 months ago - Grifols Egypt Collaborates with Orange Business to Deliver New Data Center and Communications Infrastructure, Supporting Advanced Medical Processes - Business Wire
- 2 months ago - The Schall Law Firm Is Looking Into Grifols SA For Possible Securities Related Improprieties And Stockholders Are Invited To Reach Out - Accesswire
- 2 months ago - Grifols S.A. May Have Committed Fraud And Investors Are Urged To Contact The Schall Law Firm About An Inquiry - Accesswire